Journal article
Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals
The Pediatric infectious disease journal, v 31(2)
Feb 2012
PMID: 21983213
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Although use of efficacious interventions, including antiretrovirals (ARVs), has dramatically reduced the rate of mother-to-child transmission of human immunodeficiency virus, the safety of in utero ARV exposure remains of concern.
Data regarding 1112 infants enrolled in the International Maternal Pediatric Adolescent AIDS Clinical Trials Group protocol P1025 born between 2002 and 2007 were analyzed for this study. Congenital anomalies were classified based on the Metropolitan Atlanta Congenital Defects Program guidelines. Associations between congenital anomalies and timing of first in utero exposure to ARVs were evaluated by logistic regression analysis.
Congenital anomalies were identified and confirmed in 61 of the 1112 infants, resulting in a prevalence of 5.49/100 live births (95% confidence interval, 4.22-6.99). Among the 80 anomalies identified, the organ systems involved included cardiovascular (n = 33), musculoskeletal (n = 15), renal (n = 9), genitourinary (n = 6), craniofacial (n = 4), and central nervous system (n = 2). First trimester exposure to efavirenz was associated with a significantly increased risk of congenital anomalies (odds ratio, 2.84; 95% confidence interval, 1.13-7.16). No significant associations were observed between exposure to other individual ARVs or classes of ARVs started at any time during pregnancy and infant congenital anomalies.
The observed rate of congenital anomalies in this cohort is higher than previously reported for the general population, but it is consistent with rates observed in other recent studies of children born to human immunodeficiency virus-infected women. Cardiovascular anomalies occurred most frequently. With the exception of a known teratogen (efavirenz), no statistically significant associations between in utero exposure to ARVs and congenital anomalies were identified.
Metrics
Details
- Title
- Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals
- Creators
- Katherine M Knapp - St. Jude Children's Research HospitalSusan B Brogly - Boston UniversityDaniel G Muenz - Harvard University ,Hans M L Spiegel - National Institutes of HealthDaniel H Conway - Drexel UniversityGwendolyn B ScottJeffrey T Talbot - Boston UniversityDavid E Shapiro - Harvard University ,Jennifer S Read - National Institutes of HealthP1025 Team Int Maternal Pediat
- Publication Details
- The Pediatric infectious disease journal, v 31(2)
- Publisher
- Lippincott
- Grant note
- UM1 AI106701 / NIAID NIH HHS U01 AI068616 / NIAID NIH HHS U01 AI068632 / NIAID NIH HHS UM1 AI068632 / NIAID NIH HHS HHSN267200800001C / NICHD NIH HHS UM1 AI068616 / NIAID NIH HHS U01 AI041110 / NIAID NIH HHS P30 AI073961 / NIAID NIH HHS N01-HD-9-001/HHSN267200800001C / NICHD NIH HHS U01 AI068616-01 / NIAID NIH HHS 5 U01 AI41110 / NIAID NIH HHS HHSN267200800001G / NIDDK NIH HHS U01 AI041110-05 / NIAID NIH HHS 1 U01 AI068616 / NIAID NIH HHS U01 AI068632-01 / NIAID NIH HHS AI068632 / NIAID NIH HHS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pediatrics
- Web of Science ID
- WOS:000299316500014
- Scopus ID
- 2-s2.0-84858159244
- Other Identifier
- 991019169648004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases
- Pediatrics